New targets and treatments: Understanding LDL P, Non HDL C, and ApoB

Size: px
Start display at page:

Download "New targets and treatments: Understanding LDL P, Non HDL C, and ApoB"

Transcription

1 New targets and treatments: Understanding LDL P, Non HDL C, and ApoB Samia Mora, MD, MHS Associate Physician, BWH Heart and Vascular Center; Assistant Professor of Medicine, Harvard Medical School

2 Disclosures Consultant: Cerenis, Lilly, Pfizer Institutional research grants: Atherotech Diagnostics Quest Diagnostics (in kind)

3 Topics to be covered What are the clinically important lipids or lipoproteins for CVD risk? LDL-C, non-hdl-c, Total/HDL-C LDL-P, apob Are small LDL more atherogenic than large LDL particles? Residual risk on statin therapy

4 Which woman is at higher risk? LDL cholesterol Non-HDL chol Total / HDL chol Woman A 130 mg/dl 162 mg/dl 3.1 Woman B 130 mg/dl 181 mg/dl 5.3 Mora, Circ 2009;119:2396

5 Which woman is at higher risk? Fewer Particles More Particles LDL cholesterol Non-HDL chol Total / HDL chol LDL size (NMR) LDL particle number (LDL-P, NMR) Large LDL-P Small LDL-P ApoB Woman A 130 mg/dl 162 mg/dl nm (large) 1011 nmol/l 712 nmol/l 299 nmol/l 106 mg/dl Woman B 130 mg/dl 181 mg/dl nm (small) 1723 nmol/l 360 nmol/l 1286 nmol/l 127 mg/dl Mora, Circ 2009;119:2396

6 Which woman is at higher risk? Larger LDL Size Smaller LDL Size LDL-C 130 mg/dl LDL-C 130 mg/dl Fewer Particles LDL Cholesterol More Particles LDL cholesterol Non-HDL chol Total / HDL chol LDL size (NMR) LDL particle number (LDL-P, NMR) Large LDL-P Small LDL-P ApoB Woman A 130 mg/dl 162 mg/dl nm (large) 1011 nmol/l 712 nmol/l 299 nmol/l 106 mg/dl Woman B 130 mg/dl 181 mg/dl nm (small) 1723 nmol/l 360 nmol/l 1286 nmol/l 127 mg/dl Mora, Circ 2009;119:2396

7 Topics to be covered What are the clinically important lipids or lipoproteins for CVD risk? LDL-C, non-hdl-c, Total/HDL-C LDL-P, apob Are small LDL more atherogenic than large LDL particles? Residual risk on statin therapy

8 Total/HDL-C or Non-HDL-C better than LDL-C for incident CVD Women s Health Study (N=27,673) * All P < * Relative Risk of Cardiovascular Events * * 1 LDL-C Non-HDL-C Total / HDL-C Q1 Q2 Q3 Q4 Q5 Relative risk adjusted for age, smk, menopause, hormone use, BP, BMI, diabetes Mora et al, Circulation 2009;119:931

9 ApoB and LDL-P NMR similar to Total/HDL-C or Non- HDL-C Relative Risk of Cardiovascular Events * All P < * Women s Health Study (N=27,673) * * * * 1 LDL-C Non-HDL-C Total / HDL-C ApoB LDL-P (NMR) Mora et al, Circulation 2009;119:931 Q1 Q2 Q3 Q4 Q5 Relative risk adjusted for age, smk, menopause, hormone use, BP, BMI, diabetes

10 Women s Health Study Little improvement in CVD risk classification with adding apob or LDL-P NMR to total/hdl-c C-Index NRI (p-value) % reclassified Total / HDL-C* Ref. Ref. plus LDL-P (0.52) 1.1 plus ApoB (0.02) 2.6 * Total/HDL-C plus standard CVD risk factors NRI: net reclassification index, which compares the proportion moving up or down clinical categories in cases or controls, comparing models that added LDL-P or apob to a model with total/hdl-c ratio and standard CVD risk factors Mora et al, Circulation 2009;119:931

11 Emerging Risk Factors Collaboration 26 Prospective Studies (N=139,581) Hazard Ratio (95%CI) Total Chol Non-HDL-C Total / HDL-C ApoB 1.22 ( ) 1.27 ( ) 1.32 ( ) 1.24 ( ) Hazard Ratio (95%CI) per 1-SD higher usual values Adjusted for age, sex, smoking, BP, and diabetes ERFC, JAMA 2012;307:

12 Emerging Risk Factors Collaboration No improvement in CVD risk classification with adding apob to total/hdl-c C-Index NRI (p-value) % reclassified Total / HDL-C* Ref. Ref. plus ApoB (0.34) -- plus ApoB/A-I (0.40) 1.1 * Total/HDL-C plus standard CVD risk factors NRI: net reclassification index, which compares the proportion moving up or down clinical categories in cases or controls, comparing models that added apob to a model with total/hdl-c ratio and standard CVD risk factors ERFC, JAMA 2012;307:

13 Potential clinical utility of advanced lipid testing in certain subgroups Diagnosing certain dyslipidemias (eg. familial dysbetalipoproteinemia or Type III) Individuals whose LDL-C level is discordant (inconsistent) with LDL particle measures (eg. ApoB, LDL-P) LDL-C low but ApoB or LDL-P high LDL-C high but ApoB or LDL-P low

14 Discordant LDL-C and LDL particle measures? Concordant Women s Health Study (N=27,533) LDL-C and NHDL-C 88 % 12 % Discordant Concordant NHDL-C, mg/dl Discordant Concordant Concordant Discordant r = 0.91 r = 0.91 Mora S et al, Circulation 2014; 129: LDL-C and ApoB % % % % Discordant Concordant LDL-C and LDL-P NMR Discordant Concordant ApoB, mg/dl LDL-P, nmol/l LDL-C, mg/dl Discordant Concordant Concordant Discordant LDL-C, mg/dl Discordant Concordant Concordant Discordant r = 0.78 r = 0.69 LDL-P < Median (Concordant) LDL-C, mg/dl

15 LDL-C vs NHDL-C Cumulative Probability of Incident CHD LDL-C < Median Concordant r = 0.91 NHDL-C Median (Discordant) NHDL-C < Median (Concordant) Follow-Up (Years) Concordant LDL-C Median NHDL-C Median (Concordant) NHDL-C < Median (Discordant) LDL-C vs ApoB Cumulative Probability of Incident CHD Low LDL-C, High Non-HDL-C Low LDL-C, Low Non-HDL-C ApoB Median (Discordant) ApoB < Median (Concordant) Follow-Up (Years) ApoB Median (Concordant) ApoB < Median (Discordant) LDL-C vs LDL-P Cumulative Probability of Incident CHD Low LDL-C, High ApoB Low LDL-C, Low ApoB LDL-P Median (Discordant) LDL-P < Median (Concordant) Follow-Up (Years) LDL-P Median (Concordant) LDL-P < Median (Discordant) Mora et al Circ 2014; 129: Low LDL-C, High LDL-P Low LDL-C, Low LDL-P

16 Topics to be covered What are the clinically important lipids or lipoproteins for CVD risk? LDL-C, non-hdl-c, Total/HDL-C LDL-P, apob Are small LDL more atherogenic than large LDL particles? Residual risk on statin therapy

17 Large LDL (Pattern A) Small LDL (Pattern B) Carries more cholesterol per particle Elevated in FH Elevated with high sat fat Low in countries with low fat diet (Costa Rica) High in Native Americans, Scotland (high CAD) Oxidized more rapidly Elevated in metabolic syndrome/insulin resistance Associated with low HDL-C, high TG Altered endothelial function Altered fibrinolysis Sacks and Campos, J Clin Endocrinol Metab 2003;88:

18 Both large and small LDL share atherogenic properties: Both have reduced affinity to LDL receptor In vivo, similar transit time across arterial intima Both bind arterial proteoglycans thus activating plaque progression Sacks and Campos, J Clin Endocrinol Metab 2003;88:

19 LDL size and CVD: prior studies Controversy over the importance of LDL size as independent risk factor Physicians Health Study nested case-control Adjustment for other risk factors (TG, HDL) attenuated the association of LDL size to non-significant in most studies Stampfer et al JAMA 1996;276:

20 Quebec Cardiovascular Study "Among lipid, lipoprotein, and apolipoprotein variables, apo B came out as the best and only significant predictor of CHD risk in multivariate stepwise logistic analyses (P=.002). [LDL size] as a continuous variable did not contribute to the risk of CHD after the contribution of apo B levels to CHD risk had been considered." Lamarche et al Circulation 1997; 95:69-75

21 Measurement of LDL size Most previous studies examined LDL size phenotype by GGE Limitation of gradient gel electrophoresis (GGE): Decrease in average LDL size does not necessarily translate into greater number of small LDL particles, since it could also be due to fewer large LDL particles Mora, Circ 2009;119:2396

22 More LDL particles Less LDL particles Large LDL Small LDL Large LDL Small LDL LDL size (average) Mora, Circ 2009;119:2396

23 Is the relation of LDL size with CHD confounded by LDL particle number? A confounder is associated with the risk factor and is causally related to the outcome Risk factor Outcome Confounder Alcohol CHD Smoking

24 Is the relation of LDL size with CHD confounded by LDL particle number? A confounder is associated with the risk factor and is causally related to the outcome Risk factor Outcome Confounder LDL Size CHD? Mora, Circ 2009;119:2396 LDL-P

25 Adjusting for small LDL-P unmasks the true relation of large LDL-P with IMT MESA Study (N=5538) Large LDL-P Quintiles Q1 Q2 Q3 Q4 Q P trend = 0.94 P trend <0.001 IMT (microns) Adjusted for age and sex Adjusted for age, sex, and small LDL-P Mora et al, Atherosclerosis 2007;192:211-17

26 Relation of LDL size with IMT IMT (SE) in m per 1-SD P value LDL Size (unadjusted for LDL-P) (4.5) <0.001 LDL Size (adjusted for LDL-P*) (7.2) 0.05 Models adjusted for age, sex, race, smoking, and hypertension. *correlation of LDL size with LDL-P = Mora et al, Atherosclerosis 2007;192:211-17

27 Women s Health Study: Small vs large LDL-P NMR 2.5 N=27,673 2 * P < Relative Risk of Cardiovascular Events * Small LDL-P Large LDL-P Mora et al, Circulation 2009;119:931 Q1 Q2 Q3 Q4 Q5 Relative risk adjusted for age, smk, menopause, hormone use, BP, BMI, diabetes

28 Both small and large LDL associated with increased CVD 2.5 N= * P < * Relative Risk of Cardiovascular Events * Small LDL-P Large LDL-P Large LDL-P adjusted for small LDL-P * LDL-P (Total) Mora et al, Circulation 2009;119:931 Q1 Q2 Q3 Q4 Q5 Relative risk adjusted for age, smk, menopause, hormone use, BP, BMI, diabetes

29 For type 2 diabetes, LDL particle size was strong and independent predictor Small Large Q1 Q2 Q3 Q4 Q5 P trend LDL size <0.001 * Relative risk adjusted for age, race, smk, menopause, HRT, BP, BMI, exercise, education, FHx, CRP, HbA1c Mora et al, Diabetes 2010 ; 59:

30 Large LDL associated with lower risk of diabetes Women s Health Study (N=26,836) Relative Risk of Diabetes * * * P < * * LDL-C Small LDL-P IDL-P LDL-P (Total) Large LDL-P Mora et al, Diabetes 2010 ; 59: Q1 Q2 Q3 Q4 Q5 Relative risk adjusted for age, race, smk, menopause, HRT, BP, BMI, exercise, education, FHx, CRP, HbA1c

31 JUPITER Ion Mobility LDL Subclasses and CVD Risk in placebo group Baseline LDL-C 109 mg/dl Mora et al, ATVB meeting, Toronto, 2014, manuscript in preparation

32 Topics to be covered What are the clinically important lipids or lipoproteins for CVD risk? LDL-C, non-hdl-c, Total/HDL-C LDL-P, apob Are small LDL more atherogenic than large LDL particles? Residual risk on statin therapy

33 Treating to New Targets (TNT) Multivariable Predictors of Residual Risk Final model * % or SD HR (95% CI) P BMI (per 1-SD), kg/m (1.02, 1.17) 0.01 Myocardial infarction (1.36, 1.87) <0.001 Angina (1.10, 1.68) Cerebrovascular disease (1.36, 2.19) <0.001 Peripheral vascular disease (1.09, 1.61) Congestive heart failure (1.24, 1.90) <0.001 CABG (1.08, 1.47) Calcium channel blocker (1.12, 1.54) <0.001 Aspirin (0.56, 0.81) <0.001 Baseline (per 1-SD, on-statin), mg/dl Apolipoprotein B Apolipoprotein A-I BUN (1.11, 1.28) 0.91 (0.84, 0.99) 1.10 (1.03, 1.17) < * Final model included randomized treatment, age, sex, HTN, smk, DM plus these variables Mora S et al. Circulation, 2012:125:

34 JUPITER: On-Treatment Lipids and Residual Risk Lipid or Apoipoprotein On-Treatment LDL-C 55 mg/dl SD, mg/dl HR (95% CI) * P LDL-C ( ) Non-HDL-C ( ) 0.02 Apo B ( ) Triglycerides ( ) 0.56 HDL-C ( ) 0.29 Apo A-I ( ) 0.06 * Standardized hazard ratios adjusted for age, sex, smoking, BP, glucose, BMI, family history Mora S et al., JACC 2012; 59:1521-8

35 Large inter-individual variability in response to high-intensity statin Meta-analysis of TNT, IDEAL, SPARCL, JUPITER N=18,661 Achieved LDL-C Achieved Non-HDL-C Achieved ApoB N mg/dl mg/dl mg/dl Boekholdt et al JACC 2014;64:485

36 Meta-analysis of 8 statin trials (N=38,153; No. events=5,387) On-Treatment Lipids and Residual Risk Lipid or Apoipoprotein Adjusted HR (95% CI) * P LDL-C 1.13 ( ) <0.001 Non-HDL-C 1.16 ( ) <0.001 Apo B 1.14 ( ) <0.001 Boekholdt SM et al., JAMA 2012; 307: Boekholdt SM et al., Circulation 2013; 128:

37 Differential genetic effects on statin-induced changes in LDL-C, apob, LDL-P, LDL size JUPITER, N=7046 Caucasians LDL-C NHDL-C ApoB LDL-P LDL size SNP cluster LDL size SNP cluster LDL-P SNP cluster ApoB Chu A et al, in preparation SNP cluster All

38 Which woman is at higher risk? Larger LDL Size Smaller LDL Size LDL-C 130 mg/dl LDL-C 130 mg/dl Fewer Particles LDL Cholesterol More Particles LDL cholesterol Non-HDL chol Total / HDL chol LDL size LDL particle number (LDL-P) Large LDL-P Small LDL-P ApoB Woman A 130 mg/dl 162 mg/dl nm (large) 1011 nmol/l 712 nmol/l 299 nmol/l 106 mg/dl Woman B 130 mg/dl 181 mg/dl nm (small) 1723 nmol/l 360 nmol/l 1286 nmol/l 127 mg/dl Mora, Circ 2009;119:2396

39 Topics covered What are the clinically important lipids or lipoproteins for CVD risk? LDL-C, non-hdl-c, Total/HDL-C LDL-P, apob Are small LDL more atherogenic than large LDL particles? Residual risk on statin therapy

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts.

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts. LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts Introduction While both small and large LDL particles may be atherogenic,

More information

Education. Panel. Triglycerides & HDL-C

Education. Panel. Triglycerides & HDL-C Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified

More information

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

More information

Improving cardiometabolic health in Major Mental Illness

Improving cardiometabolic health in Major Mental Illness Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic

More information

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,

More information

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics

More information

Randomized trials versus observational studies

Randomized trials versus observational studies Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease. March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding

More information

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: Robert B. Baron MD MS Professor and

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Insulin Resistance and PCOS: A not uncommon reproductive disorder

Insulin Resistance and PCOS: A not uncommon reproductive disorder Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses

More information

Overview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU

Overview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M

More information

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS

More information

C-Reactive Protein and Diabetes: proving a negative, for a change?

C-Reactive Protein and Diabetes: proving a negative, for a change? C-Reactive Protein and Diabetes: proving a negative, for a change? Eric Brunner PhD FFPH Reader in Epidemiology and Public Health MRC Centre for Causal Analyses in Translational Epidemiology 2 March 2009

More information

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Management of Lipids in 2015: Just Give them a Statin?

Management of Lipids in 2015: Just Give them a Statin? Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism

HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Understanding the Entire Lipid profile Thomas Dayspring MD, FACP

Understanding the Entire Lipid profile Thomas Dayspring MD, FACP There is only one absolute in atherosclerosis: sterols (predominantly cholesterol) entering the artery wall and being internalized by macrophages, creating foam cells (the histologic diagnostic marker

More information

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works?

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? DAVID P. GOWMAN, D.O. S E C T I O N CHIEF, CARDIOLOGY P R O G R A M D I R E C T O R, CARDIOLOGY F E L L O W S H I P B

More information

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic

More information

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.

More information

Coronary Heart Disease (CHD) Brief

Coronary Heart Disease (CHD) Brief Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs

More information

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division

More information

Diabetes and Heart Disease

Diabetes and Heart Disease Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the

More information

HDL-C, HDL-P, & HDL Function: Relation to Risk Prediction & Treatment

HDL-C, HDL-P, & HDL Function: Relation to Risk Prediction & Treatment HDL-C, HDL-P, & HDL Function: Relation to Risk Prediction & Treatment Rachel H. Mackey, PhD, MPH, FAHA Assistant Professor of Epidemiology Graduate School of Public Health University of Pittsburgh NLA

More information

Understanding diabetes Do the recent trials help?

Understanding diabetes Do the recent trials help? Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.

More information

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.

More information

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke

More information

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline Learn and Live SM ACCF/AHA Pocket Guideline Based on the 2010 ACCF/AHA Guideline Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults November 2010 Guideline for Assessment of Cardiovascular

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?

Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Henry Ginsberg, MD Columbia University College of Physicians and Surgeons Henry Ginsberg: Disclosures Research

More information

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data

More information

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell

More information

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D. Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms

More information

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:

More information

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for

More information

African Americans & Cardiovascular Diseases

African Americans & Cardiovascular Diseases Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age

More information

Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience

Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular

More information

Cardiac Rehabilitation: Strategies Approaching 2020

Cardiac Rehabilitation: Strategies Approaching 2020 ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular

More information

Testosterone and Heart Disease

Testosterone and Heart Disease Testosterone and Heart Disease By Pamela W. Smith, M.D., MPH, MS Introduction Two recent trials suggest that testosterone replacement therapy may increase the risk of heart disease and/or stroke. 1, 2

More information

Diabetes Prevention in Latinos

Diabetes Prevention in Latinos Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: Trilipix (ABT-335) Name of Active Ingredient: choline salt of fenofibric acid Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

Quantifying Life expectancy in people with Type 2 diabetes

Quantifying Life expectancy in people with Type 2 diabetes School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by

More information

MY TYPE 2 DIABETES NUMBERS

MY TYPE 2 DIABETES NUMBERS BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,

More information

Racial and ethnic disparities in type 2 diabetes

Racial and ethnic disparities in type 2 diabetes Racial and ethnic disparities in type 2 diabetes Nisa M. Maruthur, MD, MHS Assistant Professor of Medicine & Epidemiology Welch Center for Prevention, Epidemiology, & Clinical Research The Johns Hopkins

More information

PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie

PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES Richard L. Tannen, M.D., Mark Weiner, Dawei Xie GOALS OF STUDY Determine Whether Studies Using EMR Database Yield Valid Outcome Assessment Major

More information

Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease

Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ

More information

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2

More information

Cardiovascular Disease Risk Factors

Cardiovascular Disease Risk Factors Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or

More information

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant

More information

Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy

Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy International Society for Sexual Medicine 2014 Presenter: Felipe Borges

More information

Neal Rouzier responds to the JAMA article on Men and Testosterone

Neal Rouzier responds to the JAMA article on Men and Testosterone Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

YOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels

YOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels YOUR GUIDE TO Managing and Understanding Your Cholesterol Levels Our goal at the Mercy Health Heart Institute is to help you be well. Our experienced team includes cardiologists, cardiovascular surgeons,

More information

Risk Factors for Fire Fighter Cardiovascular Disease

Risk Factors for Fire Fighter Cardiovascular Disease Risk Factors for Fire Fighter Cardiovascular Disease EXECUTIVE SUMMARY Prepared by: Jefferey L. Burgess, MD, MS, MPH Mel and Enid Zuckerman College of Public Health The University of Arizona The Fire Protection

More information

Vitamin D and Cardiometabolic risk

Vitamin D and Cardiometabolic risk Vitamin D and Cardiometabolic risk 서울의대, 분당서울대병원 내과 최 성 희 2013년 대한당뇨병학회 춘계학술대회 Metabolism Of Vitamin D Risk factors for vitamin D deficiency - Aging decreased concentrations of 7-dehydro-cholesterol in

More information

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014 JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss

More information

Postmenopausal hormone replacement therapy (HRT)

Postmenopausal hormone replacement therapy (HRT) Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Linda L. Humphrey, MD, MPH; Benjamin K.S. Chan, MS; and Harold C. Sox, MD Purpose: To evaluate the value

More information

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Amit Sachdeva, MD, a Christopher P. Cannon, MD, b Prakash C. Deedwania,

More information

KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013

KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013 KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients

More information

Historically, diabetes has been considered

Historically, diabetes has been considered THE LINK BETWEEN TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE* Thomas G. Bartol, NP, CDE ABSTRACT The link between type 2 diabetes and cardiovascular disease has been amply demonstrated in numerous studies.

More information

Design and principal results

Design and principal results International Task Force for Prevention Of Coronary Heart Disease Coronary heart disease and stroke: Risk factors and global risk Slide Kit 1 (Prospective Cardiovascular Münster Heart Study) Design and

More information

Atherosclerosis of the aorta. Artur Evangelista

Atherosclerosis of the aorta. Artur Evangelista Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis

More information

Freiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.

Freiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal. Freiburg Study The Freiburg Study was conducted with 48 healthy human subjects of various ages. None of the test subjects had been diagnosed with any disease prior to the study. None were taking any type

More information

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity

More information

Evidence for Statins in

Evidence for Statins in Evidence for Statins in Secondary & Primary Prevention Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine (Cardiology) Co Director, Prevention Intervention Center University

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Supplemental Material. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

Supplemental Material. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks Supplemental Material Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks Xin-Min Li, PhD 1, W. H. Wilson Tang, MD 1,2, Marian K. Mosior, PhD 3, Ying Huang,

More information

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm Zi Ye, 1 MD, Erin Austin, 1,2 PhD, Daniel J Schaid, 2 PhD, Iftikhar J. Kullo, 1 MD Affiliations: 1 Division of Cardiovascular Diseases and

More information

Study Design and Statistical Analysis

Study Design and Statistical Analysis Study Design and Statistical Analysis Anny H Xiang, PhD Department of Preventive Medicine University of Southern California Outline Designing Clinical Research Studies Statistical Data Analysis Designing

More information

How To Treat Dyslipidemia

How To Treat Dyslipidemia An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates

More information

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?

More information

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures. JSNA Coronary heart disease 1) Key points 2) Introduction 3) National picture 4) Local picture of CHD prevalence 5) Mortality from coronary heart disease in Suffolk County 6) Trends in mortality rates

More information

The Women s Health Initiative where are we a decade later?

The Women s Health Initiative where are we a decade later? The Women s Health Initiative where are we a decade later? Henry G. Burger MIMR-PHI Institute & Jean Hailes for Women s Health, Melbourne, Australia Disclosures: Henry Burger Sources of Funding Pharmaceutical

More information

Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005

Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes

More information

Cardiovascular Risk in Diabetes

Cardiovascular Risk in Diabetes Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,

More information

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence

More information

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us Ellen Løkkegaard, Clinical Associate Professor, Ph.d. Dept. Obstetrics and Gynecology. Hillerød Hospital, University of Copenhagen

More information

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10. FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.1056/NEJMSA1107913 Niteesh K. Choudhry, MD, PhD, 1 Jerry Avorn, MD, 1 Robert J. Glynn,

More information